title: Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: Therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma.
abstract: Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) is considered to be a very useful adjunct to anatomic imaging techniques and is now primarily used for oncological indications. These indications include diagnosis, staging, and therapy monitoring. In this review, we discuss the articles in which FDG-PET is clinically used for monitoring therapy in lung and colorectal tumours, head and neck cancer, sarcoma, and hepatocellular carcinoma. It is found that the amount of FDG uptake strongly correlates with response to therapy: a decrease in FDG uptake after therapy indicates a positive response to therapy. However, this conclusion is based on small numbers of patients, whereas the exact response mechanism is still unknown. Moreover, in these case series, the interval between tumour therapy and FDG-PET, as well as the method of quantification, SUV or tumour-to-non-tumour ratios, differ per study. Finally, dynamic imaging is a recommended technique by some authors, but it is not a standard technique in clinical practice to evaluate tumour therapy. Therefore, further study is required which has to deal with these major issues before it is possible to draw definite conclusions.
authors.affiliation: Leiden University Medical Centre, Department of Radiology, Division of Nuclear Medicine, P.O. Box 9600, 2300 Leiden, The Netherlands. stokkel@mail.medfac.leidenuniv.nl
authors.forename: M P
authors.initials: MP
authors.lastname: Stokkel
authors.forename: A
authors.initials: A
authors.lastname: Draisma
authors.forename: E K
authors.initials: EK
authors.lastname: Pauwels
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000556:secondary / Q000628:therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000628:therapy; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy; D005069:Evaluation Studies as Topic; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary / Q000628:therapy; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy; D008297:Male; D009362:Neoplasm Metastasis / Q000000981:diagnostic imaging; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy; D017063:Outcome Assessment, Health Care / Q000379:methods; D012509:Sarcoma / Q000000981:diagnostic imaging / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy; D014055:Tomography, Emission-Computed
chemical_list: D000970:Antineoplastic Agents; D019788:Fluorodeoxyglucose F18